Counteraction of the Embryolethal Effects,But Not the Maternal Toxicity,of Bropirimine and Tilorone by Coadministration of Indomethacin

Abstract

Bropirimine and tilorone are immunomodulators with experimental antiviral and antitumor activities. In earlier studies, treatment with bropirimine resulted in either death of the entire litter, if given once on specific days during or prior to the period of organogenesis, or litter survival comparable with that of controls. For example, bropirimine and tilorone were both found to be embryolethal when administered orally at 400 mg/kg to Upj:TUC(SD)spf rats on day 10 of gestation. Previous studies also have shown that coadministration of progesterone with either of these immunomodulators could prevent the embryolethality but not the pronounced maternal toxicity seen concurrently. Thus, bropirimine and tilorone appear to affect maternal support of the pregnancy rather than having a direct effect on the embryos. Since administration of bropirimine or tilorone appears to mimic the luteolytic effects of prostaglandin F_2a, it was hypothesized that coadministration of the prostaglandin synthesis inhibitor indomethacin might prevent such embryolethality. Thus, indomethacin was administered s.c. in combination with bropirimine or tilorone (400 mg/kg orally on day 10 of gestation), at 0.4 or 0.8 mg/rat on days 9-11 (bropirimine experiment) or days 9-12 of gestation; the dams were killed on day 13, at which time the status of each conceptus was ascertained. Although unable to prevent maternal toxicity, which was found 24 h after administration of either immunomodulator, coadministration of indomethacin resulted in a decrease in the embryolethality associated with administration of either immunomodulator on day 10 of gestation. No live embryos were found on day 13 of gestation in five of six pregnant dams given bropirimine only, whereas in the drug-combination groups six of seven (indomethacin at 0.4 mg/day) and six of eight (indomethacin at 0.8 mg/day) pregnant dams had litters containing live embryos. In the tilorone experiment, six of eight litters were completely lost in utero in the group receiving the immunomodulator only. However, only one of four surviving dams had no live embryos in the drug-combination group that received indomethacin at 0.4 mg/day, with all eight surviving dams having live embryos in the group that received 0.8 mg/day of this drug. The results of this study and of earlier combination experiments with progesterone support the following hypothesis: bropirimine or tilorone administration to Upj:TUC-(SD)spf rats on day 10 of gestation inhibits progesterone production by the corpora lutea by a mechanism involving prostaglandin synthesis, resulting in a disruption in maternal support to the pregnant uterus and subsequent embryolethality.

Keywords

Bropirimine Tilorone Embryolethality Upj: TUC(SD)spf rats

References

Black DL , Marks TA , Branstetter DG , Kirton KT . (1991) Reversal of bropirimine developmental toxicity with progesterone. Toxicol Appl Pharmacol 108:121–8.

Branstetter DG , Marks TA , Black DL , Poppe SM , Terry RD . (1988) Bropirimine-induced necrosis of uterine decidua during gestation. Toxicologist 8:237.

Csapo AI , Wiest WG . (1969) An examination of the quantitative relationship between progesterone and the maintenance of pregnancy. Endocrinology 85:735–46.

Cummings FJ , Gelman R , Skeel RT , et al. (1981) Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-flurodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer. Cancer 48:681–5.

Friedlaender GE , Mosher MB , Mitchell MS . (1974) Effect of 2,7-Bis[2-diethylamino)ethoxy]fluoren- 9-one dihydrochloride (tilorone) upon cell-mediated immunity in mice. Cancer Res 34:304–7.

Gill TJ III. (1988) Immunological and genetic factors influencing pregnancy. In: Knobil E , Neill JD , eds. The Physiology of Reproduction. Vol 2. New York: Raven Press, 2023–42.

Grossman CJ . (1985) Interactions between the gonadal steroids and the immune system. Science 227:257–61.

Lau IF , Saksena SK , Chang MC . (1975) Effect of indomethacin, an inhibitor of prostaglandin biosynthesis on the length of pseudopregnancy in rats and hamsters. Acta Endocrinol 78:343–8.

Li HL , Wallace TL , Richard KA , Tracey DE . (1985) Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia. Cancer Res 45:532–8.

10.

Marks TA , Black DL , Terry RD , Branstetter DG , Kirton KT . (1990) Variability in the developmental toxicity of bropirimine with the day of insemination. Teratology 42:55–66.

11.

Marks TA , Black DL , Tracey DE . (1993) Reversal of human recombinant interleukin 1β (rhIL-β) embryolethality with progesterone. Teratology 47:406.

12.

Marks TA , Poppe SM . (1988) Developmental toxicity of bropirimine in rats after oral administration. Teratology 38:7–14.

13.

Mitchell MD , Edwin S , Romero RJ . (1990) Prostaglandin biosynthesis by human decidual cells: effects of inflammatory mediators. Prostaglandins Leukolrienes Essential Fatty Acids 41:35–8.

14.

Niswender GD , Nett TM . (1988) The corpus luteum and its control. In: Knobil E , Neill JD , eds. The Physiology of Reproduction. Vol 1. New York: Raven Press, 489–525.

15.

Pharriss BB , Wyngarden LJ . (1969) The effect of prostaglandin F2α on the progestogen content of ovaries from pseudopregnant rats. Proc Soc Exp Biol Med 130:92–4.

16.

Poppe SM , Marks TA , Renis HE . (1989) Bropirimine-induced embryolethality after oral administration to the pregnant rat. Fund Appl Toxicol 13:87–101.

17.

Poyser NL . (1981) Uterine prostaglandins in luteolysis and menstruation. In: Prostaglandins in Reproduction. New York: Research Studies Press, 83–143.

18.

Richard KA , Mortensen RF , Tracey DE . (1987) Cytokines involved in the augmentation of murine natural killer cell activity by pyrimidinones in vivo. J Biol Response Mod 6:647–63.

19.

Richter P , Wampler GL , Kupermine M , Regelson W . (1977) Tilorone: Phase II study. In: Modulation of Host Immune Resistance in the Prevention or Treatment of Induced Neoplasias. Washington, DC: U.S. Government Printing Office, 141–3.

20.

Rios A , Stringfellow DA , Fitzpatrick FA , Reele SB , Gutknecht GD , Hersh EM . (1986) Phase I study of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP), an oral interferon inducer in cancer patients. J Biol Response Mod 5:330–8.

21.

Rohovsky MW , Newberne JW , Gibson JP . (1971) Preclinical toxicity studies with tilorone hydrochloride, an oral interferon inducer. Toxicol Appl Pharmacol 19:415.

22.

Snedecor GW , Cochran WG . (1967) Statistical Methods. Ames, la: Iowa State University Press.

23.

Stringfellow DA . (1981a) 6-Aryl primidinoles: interferon inducers, immunomodulators, antiviral and antineoplastic agents. Prog Cancer Res Ther 16:215–28.

24.

Stringfellow DA . (1981b) Induction of interferon with low molecular weight compounds: fluorenone esters, ethers (tilorone) and pyrimidinones. Methods Enzymol 78:262–87.

25.

Terry RD , Marks TA , Hamilton RD , Pitts TW , Renis HE . (1992) Prevention of tilorone developmental toxicity with progesterone. Teratology 46:237–50.

26.

Vane JR . (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 231:232–5.

27.

Wampler GL , Kupermine M , Regelson W . (1973) Phase I study of tilorone, a non-marrow depressing antitumor agent. Cancer Chemother Rep 57:209–17.

28.

Wegmann TG . (1986) The paradox of histocompatability and mammalian pregnancy. In: Hoffman GW , Levy JG , Nepom GT , eds. Paradoxes in Immunology. Boca Raton, FL: CRC Press, 209–306.

29.

Weiss JN , Weinberg RS , Regelson W . (1980) Keratopathy after oral administration of tilorone hydrochloride. Am J Ophthalmol 89:46–53.